Wells Fargo launched its coverage of Sarepta Therapeutics (NASDAQ:SRPT) with an Overweight recommendation, citing commercial ...

One day after the European Medicines Agency requested that three clinical trials of Elevidys be placed on hold after the ...

A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 ...

Explore Solid Biosciences’ potential with promising SGT-003 trial results for DMD, strong financials, and market recovery ...

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...

April 4 (Reuters) - Sarepta Therapeutics (SRPT.O), opens new tab said on Friday it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last ...

Wells Fargo initiated coverage of Sarepta (SRPT) with an Overweight rating and $115 price target Despite the recent Gr5 AE case, the firm ...

Learn more about whether Alvotech or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The Swiss drugmaker, which holds European rights to Elevidys, suspended three trials while researchers investigate the death ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...

In March, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.